Overview

Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2028-03-31

Target enrollment:

Participant gender:

Summary

This study is to evaluate the efficacy of neoadjuvant long-term treatment with tislelizumab in combination with SOX in the treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Liaoning Cancer Hospital & Institute

Treatments:

tislelizumab